Cargando…

The Right Treatment Strategy for the Right Patient: A Biomarker-Driven Approach to Neoadjuvant vs. Surgery-First Management of Resectable and Borderline Resectable Pancreatic Cancer

SIMPLE SUMMARY: Routine neoadjuvant therapy for resectable and borderline resectable pancreatic cancer is gaining popularity, but its true oncological benefit remains disputed. Whilst the genotypic and phenotypic heterogeneity of pancreatic cancer is becoming increasingly appreciated, there is curre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nahm, Christopher B., Turchini, John, Sahni, Sumit, Moon, Elizabeth, Itchins, Malinda, Arena, Jennifer, Chou, Angela, Colvin, Emily K., Howell, Viive M., Pavlakis, Nick, Clarke, Stephen, Samra, Jaswinder S., Gill, Anthony J., Mittal, Anubhav
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367299/ https://www.ncbi.nlm.nih.gov/pubmed/35892879 http://dx.doi.org/10.3390/cancers14153620

Ejemplares similares

Optimal Upfront Treatment in Surgically Resectable Pancreatic Cancer Candidates: A High-Volume Center Retrospective Analysis
por: Maloney, Sarah, et al.
Publicado: (2021)

Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy
por: Sahni, Sumit, et al.
Publicado: (2020)

The Prognostic and Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Lymphocyte-to-Monocyte Ratio (LMR) as Biomarkers in Resected Pancreatic Cancer
por: Maloney, Sarah, et al.
Publicado: (2023)

Gene expression profiling of pancreatic ductal adenocarcinomas in response to neoadjuvant chemotherapy
por: Sahni, Sumit, et al.
Publicado: (2023)

The role of diagnostic, prognostic, and predictive biomarkers in the management of early pancreatic cancer
por: Maloney, Sarah, et al.
Publicado: (2023)

Drain fluid biomarkers for prediction and diagnosis of clinically relevant postoperative pancreatic fistula: A narrative review
por: Rykina-Tameeva, Nadya, et al.
Publicado: (2022)

Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy?
por: Gillson, Josef, et al.
Publicado: (2020)

Corrigendum: Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas
por: Mehta, Shreya, et al.
Publicado: (2021)

Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas
por: Mehta, Shreya, et al.
Publicado: (2021)

Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer
por: Janssen, Quisette P., et al.
Publicado: (2020)

Editorial: Neoadjuvant treatment for resectable and borderline resectable pancreatic cancer
por: Massani, Marco, et al.
Publicado: (2023)

Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?
por: Versteijne, Eva, et al.
Publicado: (2022)

Borderline resectable pancreatic cancer and vascular resections in the era of neoadjuvant therapy
por: Mikulic, Danko, et al.
Publicado: (2021)

The role of staging laparoscopy in pancreatic adenocarcinoma and its effect on patients’ survival
por: Jambor, Maxwell A., et al.
Publicado: (2022)

Optimizing neoadjuvant radiotherapy for resectable and borderline resectable pancreatic cancer using protons
por: Nichols, Romaine Charles, et al.
Publicado: (2019)

The quantum leap in therapeutics for advanced ALK+ non-small cell lung cancer and pursuit to cure with precision medicine
por: Itchins, Malinda, et al.
Publicado: (2022)

Do you get the GIST? Successful resection of a giant 3.5 kg gastrointestinal stromal tumour
por: Borruso, Luca, et al.
Publicado: (2022)

Autophagy: A Key Player in Pancreatic Cancer Progression and a Potential Drug Target
por: Gillson, Josef, et al.
Publicado: (2022)

Heterogeneous tumor microenvironment in pancreatic ductal adenocarcinoma: An emerging role of single‐cell analysis
por: Byeon, Sooin, et al.
Publicado: (2023)

Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma
por: Trinh, Katherine V., et al.
Publicado: (2020)

Postoperative pancreatic fistula: a review of traditional and emerging concepts
por: Nahm, Christopher B, et al.
Publicado: (2018)

Survival outcome and prognostic factors of neoadjuvant treatment followed by resection for borderline resectable pancreatic cancer
por: Kim, Hyeong Seok, et al.
Publicado: (2017)

Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma
por: Iyengar, Siddharth, et al.
Publicado: (2021)

Circulating and disseminated tumor cells in pancreatic cancer and their role in patient prognosis: a systematic review and meta-analysis
por: Stephenson, David, et al.
Publicado: (2017)

Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
por: Ahern, Elizabeth, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
por: Alva-Ruiz, Roberto, et al.
Publicado: (2021)

Meta‐analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer
por: Versteijne, E., et al.
Publicado: (2018)

Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Cloyd, Jordan M., et al.
Publicado: (2020)

Drain fluid biomarkers for the diagnosis of clinically relevant postoperative pancreatic fistula: a diagnostic accuracy systematic review and meta-analysis
por: Rykina-Tameeva, Nadya, et al.
Publicado: (2023)

Breakthrough 5-year survival with pembrolizumab in Keynote-001 study: horizon shifting in advanced non-small cell lung cancer with immune check point inhibition
por: de Silva, Madhawa, et al.
Publicado: (2020)

Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors
por: Mehta, Shreya, et al.
Publicado: (2015)

Short-Course or Total Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer - Current Status and Future Perspectives
por: Labori, Knut Jørgen
Publicado: (2022)

Neoadjuvant chemotherapy for borderline resectable and upfront resectable pancreatic cancer increasing overall survival and disease-free survival?
por: Fossaert, Violette, et al.
Publicado: (2022)

Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer
por: Oshima, Minoru, et al.
Publicado: (2020)

Prognostic value of neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomized controlled trials
por: Liu, Shangtong, et al.
Publicado: (2023)

Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma
por: Katz, Matthew H G, et al.
Publicado: (2023)

Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
por: Hu, Qiancheng, et al.
Publicado: (2019)

Resection of the Right Half of the Colon (Hemicolectomy)
por: Arawattigi, S. D.
Publicado: (1944)

Neoadjuvant FOLFIRINOX Application in Borderline Resectable Pancreatic Adenocarcinoma: A Retrospective Cohort Study
por: Paniccia, Alessandro, et al.
Publicado: (2014)

Neoadjuvant chemotherapy and radiotherapy outcomes in borderline‐resectable and locally‐advanced pancreatic cancer patients
por: Botta, Gregory P., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5h4s5tqfgbeun05he720qb9r6o